Literature DB >> 30810094

Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer.

Susana Ramalho1, Liliana Al De Angelo Andrade2, Cássio Cardoso Filho1, Rodrigo de Andrade Natal3, Marina Pavanello4, Amanda Canato Ferracini4, Luis Felipe Sallum1, Luis Otávio Sarian1, Sophie Derchain1.   

Abstract

The objective of this study is to evaluate the relationship between discoidin domain receptor 2 (DDR2) and miR-182 expression with response to platinum-based chemotherapy and survival in women with high-grade serous ovarian cancer (HGSOC). We evaluated 78 women with HGSOC stages I-IV, diagnosed between 1996 and 2013, and followed up until 2016. DDR2 expression was assessed using immunohistochemistry on tissue microarray slides. The microRNAs were evaluated by qRT-PCR. DDR2 expression was high in 11 (14.1%) women. PFS was significantly lower in women with FIGO stage I/II - versus III/IV, post-surgery residual disease and high expression of DDR2. Women with postsurgery residual disease, FIGO stage I/II - versus III/IV and DDR2 expression had worse OS, but only post-surgery residual disease remained an independent prognostic factor for worse OS in multivariable analysis. miR-182 expression levels were significantly lower in patients harboring tumors with higher expression of DDR2 (p < 0.001). In this relatively large cohort of women with HSGOC, higher DDR2 expression was associated with lower miR-182 levels and worse PFS, suggesting that these molecules may be associated with mechanisms of HGSOC progression.

Entities:  

Keywords:  Epithelial ovarian cancer; biomarkers; drug resistance; prognosis; survival

Mesh:

Substances:

Year:  2019        PMID: 30810094     DOI: 10.1177/1010428318823988

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

Review 1.  Prognostic and Clinicopathologic Significance of Discoidin Domain Receptors in Different Human Malignancies: A Meta-Analysis.

Authors:  Gordon A Ferns; Sheida Shabanian; Milad Shahini Shams Abadi; Ahmadshah Farhat; Mohammad-Hassan Arjmand
Journal:  Gastrointest Tumors       Date:  2021-08-05

2.  Identification of Stably Expressed Reference microRNAs in Epithelial Ovarian Cancer.

Authors:  Joanna Lopacinska-Joergensen; Douglas V N P Oliveira; Claus K Hoegdall; Estrid V Hoegdall
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 3.  Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.

Authors:  Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan
Journal:  Genes Dis       Date:  2020-12-01

4.  miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R.

Authors:  Lili Ren; Yong Li; Qun Zhao; Liqiao Fan; Bibo Tan; Aimin Zang; Hua Yang
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

5.  Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.

Authors:  Natalie J Hannan; Paul A Cohen; Sally Beard; Sanela Bilic; Bonnie Zhang; Stephen Tong; Clare Whitehead; Lisa Hui
Journal:  Gynecol Oncol Rep       Date:  2021-12-02

Review 6.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

7.  Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.

Authors:  Bo Young Jeong; Kyung Hwa Cho; Se-Hee Yoon; Chang Gyo Park; Hwan-Woo Park; Hoi Young Lee
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.